The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Earnings quality 44/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Arcadia Biosciences, Inc. reports it. History and quarterly detail are in the app.
- Product$4.9M
Leadership changes
From Arcadia Biosciences, Inc.'s own filings, the day they're filed.
- Albert D. Bolles · director · departureeff. 2026-02-04
- Mark Kawakami · chief financial officer · departureeff. 2025-09-12
- Thomas J. Schaefer · Chief Executive Officer · departureeff. 2025-08-28
Latest filings
- 8-K · Company announcement2026-06-15
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-04-03
- 8-K · Company announcement2026-03-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Arcadia Biosciences, Inc., every answer cited🔒
- The Intelligence Brief — added when Arcadia Biosciences, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.